logo
  Join        Login             Stock Quote

Seven Stocks To Invest In Biotechnology & Drugs

 June 29, 2011 09:58 AM
 


Yesterday, stocks closed higher for a second day as optimism that Europe would soon find a solution to Greece's debt woes lured investors into riskier investments. Currently, biotechnology and drugs is one of the best performing sectors, as there are 111 companies that have a relative strength at or above 80.

Out of the 300 biotechnology and drugs stocks that are generally tracked, prices of 195 stocks increased, and 87 decreased while 18 remained unchanged. So, the breadth was encouraging. Out of those 300 stocks, we will pick seven stocks that can be fairly termed ‘bullish' in the next three to twelve months.

Percentage change in share prices ranged from a gain of 16.67 percent (Palatin Technologies Inc. (AMEX:PTN)) to a loss of 11.64 percent (Aoxing Pharmaceutical Company Inc. (AMEX:AXN)). Absolute change in price ranged from a loss of $0.73 (Endo Pharmaceuticals (Nasdaq:ENDP)) to a gain of $3.74 (Biogen Idec Inc. (Nasdaq:BIIB))

[Related -Walgreen Company (NYSE:WAG) Q1 Earnings Preview: What To Watch?]

Seattle Genetics Inc. (Nasdaq:SGEN) is an automatic choice (kindly look at ‘Should you invest in Seattle Genetics, Inc. (Nasdaq:SGEN)' article). We will examine the outliers (PTN, AXN, ENDP, and BIIB) to see if they present any investment or trading opportunities. AXN, and PTN don't pass the cut as they are micro cap companies.

Endo Pharmaceuticals (Nasdaq:ENDP)

[Related -Can Abbvie Inc (NYSE:ABBV) Trump Gilead Sciences, Inc.'S (NASDAQ:GILD) HCV Lead?]

Yesterday, ENDP closed trading at $39.01, compared with a 52-week range of $21.30 to $44.53. The company develops and markets branded and generic prescription pharmaceuticals used primarily to treat and manage pain. Recently, the company has diversified its offerings to include pharmaceuticals to treat urologic conditions, urology services and devices, and expanded its generic drug presence. Following the 2010 acquisition of Qualitest, ENDP estimated it had the sixth largest U.S. generic pharmaceutical business by total prescriptions.

Recently, the company completed a $2.9 billion acquisition of American Medical Systems (AMS), which helps it further diversify its presence into urologic medical devices and continue pushing beyond its legacy pain pharmaceuticals. The company's focus on debt reduction after recent acquisitions should bolster its balance sheet. I expect the AMS deal to be highly accretive to ENDP's earnings and anticipate ENDP updating guidance to reflect the deal's closing in early August. As a result, I expect its 2011 adjusted EPS estimate to touch $4.44 and 2012's to touch $5.25. Based on these estimates, my 12-month target price is $51.

Biogen Idec Inc.


Next Page >>123
iOnTheMarket Premium
Advertisement

Advertisement


Comments Closed


rss feed

Latest Stories

article imageIntegrated Device Technology Inc. (IDTI) Q1 Earnings Preview: Another Beat and Pop?

Integrated Device Technology Inc. (NASDAQ:IDTI) will issue first quarter 2015 financial results on July 28, read on...

article imageHerbalife Ltd. (NYSE:HLF) Q2 Earnings Preview: The Potential To Shock?

Herbalife Ltd. (NYSE:HLF) will release its second quarter 2014 financial results after the close of trading read on...

article imageHealth Net, Inc. (HNT): Potential to Be Huge Winners Says Bank of America

As of this keystroke, Health Net, Inc. (NYSE: HNT) shares are up around 4% on the day. The managed health read on...

article imageHomeAway, Inc. (AWAY) Q2 Earnings Preview: Top and Bottom Line Bullish Surprise?

HomeAway, Inc. (NASDAQ:AWAY) will report its financial results for the second quarter ended June 30, 2014 read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.